CJC-1295 is a growth hormone-releasing hormone analogue studied for its ability to prolong stimulation of the GH–IGF-1 axis. The best-known early human studies investigated a long-acting form. Precise chemical identity matters because commercial names and research names are not always used consistently.
What the human studies showed
Two short randomized, placebo-controlled studies in healthy adults measured pharmacokinetics, GH, IGF-1 and safety observations. They reported sustained changes in hormone concentrations. Their duration and objectives did not establish long-term benefits for aging, body composition, recovery or disease prevention. Teichman and colleagues, 2006
A separate study examined GH secretion patterns after the long-acting analogue. It found that pulsatile secretion persisted, while other features of the hormonal exposure changed. Preserved pulses should not be interpreted as proof that the entire hormonal state remained physiologically normal or harmless. Ionescu and Frohman, 2006
Why naming needs care
The CJC-1295 studied by Ionescu and Frohman binds to endogenous albumin, prolonging its persistence and hormonal exposure. Ionescu and Frohman, 2006 A label containing “CJC-1295” does not establish that the material is this same molecule. Variants marketed as “with DAC” or “without DAC” cannot be assumed equivalent: an altered albumin-binding feature can change exposure and make the original study inapplicable.
What remains necessary
A useful clinical claim needs evidence for the exact intervention, an appropriate population and a meaningful endpoint. Short-term hormone changes and a limited safety sample cannot establish broad long-term safety.
FDA has published safety concerns involving CJC-1295, including limited clinical information and reported serious reactions. That risk information should be read separately from any current compounding-policy status. FDA: Bulk substances with potential safety risks
No dosing or use recommendation follows from these studies. Regulatory statements require a fresh jurisdiction-specific review before publication.
You might be wondering
Where this question leads.
Original related-reading note
Related reading: E02, E07, E13.
Follow the source material.
Links are preserved from the supplied draft manuscripts. Linked sources may change. Regulatory wording needs a fresh specialist check before public launch.
